Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000596571 | SCV000707535 | uncertain significance | not provided | 2017-04-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000596571 | SCV001041975 | likely benign | not provided | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004686594 | SCV005181330 | uncertain significance | Inborn genetic diseases | 2024-04-04 | criteria provided, single submitter | clinical testing | The c.13343A>G (p.D4448G) alteration is located in exon 63 (coding exon 62) of the USH2A gene. This alteration results from a A to G substitution at nucleotide position 13343, causing the aspartic acid (D) at amino acid position 4448 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001829676 | SCV002088268 | likely benign | Usher syndrome type 2A | 2020-07-02 | no assertion criteria provided | clinical testing |